• Caris Life Sciences to Present at Cowen and Company 39th Annual Health Care Conference

    IRVING, Texas, March 5, 2019 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced that Brian Brille, Vice Chairman of the Company, will present at the Cowen and Company 39th Annual Health Care Conference on Monday, March 11, 2019, at 1:30 p.m. Eastern time. … Read More

  • Caris Life Sciences Launches Whole Transcriptome Sequencing (WTS) with Novel MI Transcriptome™

    New test provides most comprehensive tumor RNA analysis in the industry, including rare fusion detection IRVING, Texas, February 5, 2019 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the launch of its newest addition to its comprehensive genomic profiling offering, MI Transcriptome™, which … Read More

  • Caris Life Sciences Names Chief Communications Officer

    IRVING, Texas, January 21, 2019 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced that Srikant (Sri) Ramaswami, has joined the company as Vice President and Chief Communications Officer. Ramaswami brings to Caris more than two decades of healthcare communications experience, and has held … Read More

  • Caris Life Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference

    IRVING, Texas, Jan. 3, 2019 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that David D. Halbert, Chairman and Chief Executive Officer, will present at the 2019 J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019, at 11 a.m. PST (2 p.m. EST) … Read More

  • Caris Life Sciences Raises $150 Million in Growth Capital from TPG Sixth Street Partners

    Caris to accelerate development of Next Generation Profiling to analyze whole exome, whole transcriptome and the complete cancer proteome using its proprietary artificial intelligence (AI) analytic engine, DEAN, on tens of thousands of patients with mature clinical outcomes Caris is engaged in some of the most important translational research using the proprietary ADAPT Biotargeting System … Read More